Cantor Fitzgerald Estimates YMAB FY2026 Earnings

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Y-mAbs Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings per share of ($1.04) for the year. The consensus estimate for Y-mAbs Therapeutics' current full-year earnings is ($0.65) per share.

A number of other equities research analysts have also weighed in on YMAB. HC Wainwright reduced their price objective on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Morgan Stanley cut their price target on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a research note on Wednesday, March 5th. Wedbush reaffirmed an "outperform" rating and set a $18.00 price objective (down from $21.00) on shares of Y-mAbs Therapeutics in a research report on Wednesday, May 28th. Truist Financial dropped their price objective on Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Finally, Bank of America cut Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 target price for the company. in a research note on Tuesday, April 22nd. Two equities research analysts have rated the stock with a sell rating, seven have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Y-mAbs Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $15.60.

Y-mAbs Therapeutics Trading Up 1.7%

NASDAQ:YMAB traded up $0.08 during mid-day trading on Tuesday, hitting $4.71. The stock had a trading volume of 472,812 shares, compared to its average volume of 305,064. Y-mAbs Therapeutics has a twelve month low of $3.55 and a twelve month high of $16.11. The stock has a 50-day simple moving average of $4.44 and a two-hundred day simple moving average of $5.96. The company has a market capitalization of $213.29 million, a PE ratio of -8.72 and a beta of 0.52.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.10. The company had revenue of $20.90 million for the quarter, compared to the consensus estimate of $19.97 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%.

Institutional Trading of Y-mAbs Therapeutics

A number of large investors have recently made changes to their positions in YMAB. KLP Kapitalforvaltning AS acquired a new position in Y-mAbs Therapeutics during the fourth quarter worth approximately $46,000. Brooklyn Investment Group increased its holdings in shares of Y-mAbs Therapeutics by 4,563.8% in the 1st quarter. Brooklyn Investment Group now owns 5,923 shares of the company's stock valued at $26,000 after acquiring an additional 5,796 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Y-mAbs Therapeutics in the 1st quarter valued at $49,000. Corton Capital Inc. purchased a new stake in Y-mAbs Therapeutics in the 1st quarter valued at $55,000. Finally, ProShare Advisors LLC purchased a new stake in Y-mAbs Therapeutics in the 4th quarter valued at $99,000. 70.85% of the stock is owned by institutional investors and hedge funds.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.